STATKING Clinical Services Reaches 25 Year Milestone

Cincinnati, OH – November 18, 2014 – STATKING Clinical Services (SCS), a privately-owned, Cincinnati-based Contract Research Organization (CRO), has observed its 25th anniversary of service to the pharmaceutical and medical device industries. Since opening its doors in 1989, the CRO has provided services on over 300 clinical studies. STATKING has progressed from a biostatistics consulting company to a full service CRO providing a complete solution for the management of clinical trials. STATKING has been a key partner to its Client companies in multiple regulatory product approvals in multiple therapeutic areas. STATKING has provided valued, strategic input to over 100 companies in STATKING's niche market of emerging pharmaceutical and medical device companies. "Our progress as a CRO is truly a testament to the hard work of many dedicated employees over the past 25 years." commented Dennis W. King, Founder, President and CEO of STATKING Clinical Services, "We are proud of the dedication, honesty and integrity that our people and our management have shown in the operation of this company." Rod Lashley, Executive Vice President and Co-owner of STATKING,added "It is truly rewarding to know that we have helped so many companies obtain regulatory approval for their products. We look forward to continuing to be a valued partner for our clients."

About STATKING Clinical Services

STATKING Clinical Services provides clinical trial services (clinical trial management, protocol development, biostatistics, clinical data management, clinical study monitoring, medical writing, medical monitoring, contract laboratory services, safety reporting, and project management) for clinical trials for the regulatory approval of novel drug and medical device products. The company is headquartered in Fairfield, OH. The company has provided support on 12 NDAs, 13 PMAs and multiple NADAs over the past 25 years of service to the pharmaceutical, medical device and animal health industries. For more information, visit

STATKING Clinical Services
Rod Lashley, Executive Vice President 513-858-2989 x303
[email protected]

Suggested Articles

Galecto picked up $64 million to push its lead lung disease treatment toward an approval in Europe and fund midstage studies for its other programs.

The financing, which attracted support from Roche Venture Fund, sets Palladio up to test its vasopressin V2 receptor antagonist in a kidney disease.

A new atlas of 500,000 cardiac cells could help researchers better understand how a healthy heart operates—and what goes wrong in heart disease.